title: Food and Drug Administration's Obesity Drug Guidance Document: a short history.
authors.affiliation: Division of Metabolism and Endocrinology Products, Office of Drug Evaluation II, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA. eric.colman@fda.hhs.gov
authors.forename: Eric
authors.initials: E
authors.lastname: Colman
mesh_terms: D000293:Adolescent; D000328:Adult; D026683:Advisory Committees / Q000266:history; D000368:Aged; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000266:history* / Q000627:therapeutic use; D052938:Bariatric Medicine / Q000266:history; D015992:Body Mass Index; D002648:Child; D003226:Congresses as Topic / Q000266:history; D003503:Cyclobutanes / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D017277:Drug Approval; D055808:Drug Discovery; D005260:Female; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009765:Obesity / Q000188:drug therapy* / Q000453:epidemiology / Q000266:history; D017063:Outcome Assessment, Health Care; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012015:Reference Standards; D000077285:Rimonabant; D056737:Safety-Based Drug Withdrawals; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration / Q000266:history*
chemical_list: D019440:Anti-Obesity Agents; D003503:Cyclobutanes; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant; C058254:sibutramine